Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 31

1.

Age-Related Impaired Efficacy of Bone Marrow Cell Therapy for Myocardial Infarction Reflects a Decrease in B Lymphocytes.

An S, Wang X, Ruck MA, Rodriguez HJ, Kostyushev DS, Varga M, Luu E, Derakhshandeh R, Suchkov SV, Kogan SC, Hermiston ML, Springer ML.

Mol Ther. 2018 Jul 5;26(7):1685-1693. doi: 10.1016/j.ymthe.2018.05.015. Epub 2018 Jun 15.

PMID:
29914756
2.

High-Throughput Flow Cytometry Identifies Small-Molecule Inhibitors for Drug Repurposing in T-ALL.

Perez DR, Nickl CK, Waller A, Delgado-Martin C, Woods T, Sharma ND, Hermiston ML, Loh ML, Hunger SP, Winter SS, Chigaev A, Edwards B, Sklar LA, Matlawska-Wasowska K.

SLAS Discov. 2018 May 1:2472555218774248. doi: 10.1177/2472555218774248. [Epub ahead of print]

PMID:
29746793
3.

Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia.

Bride KL, Vincent TL, Im SY, Aplenc R, Barrett DM, Carroll WL, Carson R, Dai Y, Devidas M, Dunsmore KP, Fuller T, Glisovic-Aplenc T, Horton TM, Hunger SP, Loh ML, Maude SL, Raetz EA, Winter SS, Grupp SA, Hermiston ML, Wood BL, Teachey DT.

Blood. 2018 Mar 1;131(9):995-999. doi: 10.1182/blood-2017-07-794214. Epub 2018 Jan 5.

PMID:
29305553
4.

Manipulating DNA damage-response signaling for the treatment of immune-mediated diseases.

McNally JP, Millen SH, Chaturvedi V, Lakes N, Terrell CE, Elfers EE, Carroll KR, Hogan SP, Andreassen PR, Kanter J, Allen CE, Henry MM, Greenberg JN, Ladisch S, Hermiston ML, Joyce M, Hildeman DA, Katz JD, Jordan MB.

Proc Natl Acad Sci U S A. 2017 Jun 13;114(24):E4782-E4791. doi: 10.1073/pnas.1703683114. Epub 2017 May 22.

5.

JAK/STAT pathway inhibition overcomes IL7-induced glucocorticoid resistance in a subset of human T-cell acute lymphoblastic leukemias.

Delgado-Martin C, Meyer LK, Huang BJ, Shimano KA, Zinter MS, Nguyen JV, Smith GA, Taunton J, Winter SS, Roderick JR, Kelliher MA, Horton TM, Wood BL, Teachey DT, Hermiston ML.

Leukemia. 2017 Dec;31(12):2568-2576. doi: 10.1038/leu.2017.136. Epub 2017 May 9.

6.

Targeting childhood, adolescent and young adult non-Hodgkin lymphoma: therapeutic horizons.

Galardy PJ, Bedekovics T, Hermiston ML.

Br J Haematol. 2016 May;173(4):625-36. doi: 10.1111/bjh.14016. Epub 2016 Mar 27. Review.

PMID:
27019108
7.

MAPK signaling cascades mediate distinct glucocorticoid resistance mechanisms in pediatric leukemia.

Jones CL, Gearheart CM, Fosmire S, Delgado-Martin C, Evensen NA, Bride K, Waanders AJ, Pais F, Wang J, Bhatla T, Bitterman DS, de Rijk SR, Bourgeois W, Dandekar S, Park E, Burleson TM, Madhusoodhan PP, Teachey DT, Raetz EA, Hermiston ML, Müschen M, Loh ML, Hunger SP, Zhang J, Garabedian MJ, Porter CC, Carroll WL.

Blood. 2015 Nov 5;126(19):2202-12. doi: 10.1182/blood-2015-04-639138. Epub 2015 Aug 31.

8.

Unbiased modifier screen reveals that signal strength determines the regulatory role murine TLR9 plays in autoantibody production.

Mills RE, Lam VC, Tan A, Cresalia N, Oksenberg N, Zikherman J, Anderson M, Weiss A, Hermiston ML.

J Immunol. 2015 Apr 15;194(8):3675-86. doi: 10.4049/jimmunol.1500026. Epub 2015 Mar 13.

9.

Efficacy of JAK/STAT pathway inhibition in murine xenograft models of early T-cell precursor (ETP) acute lymphoblastic leukemia.

Maude SL, Dolai S, Delgado-Martin C, Vincent T, Robbins A, Selvanathan A, Ryan T, Hall J, Wood AC, Tasian SK, Hunger SP, Loh ML, Mullighan CG, Wood BL, Hermiston ML, Grupp SA, Lock RB, Teachey DT.

Blood. 2015 Mar 12;125(11):1759-67. doi: 10.1182/blood-2014-06-580480. Epub 2015 Feb 2.

10.

Wnt inhibition leads to improved chemosensitivity in paediatric acute lymphoblastic leukaemia.

Dandekar S, Romanos-Sirakis E, Pais F, Bhatla T, Jones C, Bourgeois W, Hunger SP, Raetz EA, Hermiston ML, Dasgupta R, Morrison DJ, Carroll WL.

Br J Haematol. 2014 Oct;167(1):87-99. doi: 10.1111/bjh.13011. Epub 2014 Jul 4.

11.

The genetic basis of early T-cell precursor acute lymphoblastic leukaemia.

Zhang J, Ding L, Holmfeldt L, Wu G, Heatley SL, Payne-Turner D, Easton J, Chen X, Wang J, Rusch M, Lu C, Chen SC, Wei L, Collins-Underwood JR, Ma J, Roberts KG, Pounds SB, Ulyanov A, Becksfort J, Gupta P, Huether R, Kriwacki RW, Parker M, McGoldrick DJ, Zhao D, Alford D, Espy S, Bobba KC, Song G, Pei D, Cheng C, Roberts S, Barbato MI, Campana D, Coustan-Smith E, Shurtleff SA, Raimondi SC, Kleppe M, Cools J, Shimano KA, Hermiston ML, Doulatov S, Eppert K, Laurenti E, Notta F, Dick JE, Basso G, Hunger SP, Loh ML, Devidas M, Wood B, Winter S, Dunsmore KP, Fulton RS, Fulton LL, Hong X, Harris CC, Dooling DJ, Ochoa K, Johnson KJ, Obenauer JC, Evans WE, Pui CH, Naeve CW, Ley TJ, Mardis ER, Wilson RK, Downing JR, Mullighan CG.

Nature. 2012 Jan 11;481(7380):157-63. doi: 10.1038/nature10725.

12.

Requirement for CD45 in fine-tuning mast cell responses mediated by different ligand-receptor systems.

Grochowy G, Hermiston ML, Kuhny M, Weiss A, Huber M.

Cell Signal. 2009 Aug;21(8):1277-86. doi: 10.1016/j.cellsig.2009.03.018. Epub 2009 Mar 27.

PMID:
19332117
13.

Oncogenic Kras initiates leukemia in hematopoietic stem cells.

Sabnis AJ, Cheung LS, Dail M, Kang HC, Santaguida M, Hermiston ML, Passegué E, Shannon K, Braun BS.

PLoS Biol. 2009 Mar 17;7(3):e59. doi: 10.1371/journal.pbio.1000059.

14.

CD45, CD148, and Lyp/Pep: critical phosphatases regulating Src family kinase signaling networks in immune cells.

Hermiston ML, Zikherman J, Zhu JW.

Immunol Rev. 2009 Mar;228(1):288-311. doi: 10.1111/j.1600-065X.2008.00752.x. Review. Erratum in: Immunol Rev. 2009 May;229(1):387.

15.

Differential impact of the CD45 juxtamembrane wedge on central and peripheral T cell receptor responses.

Hermiston ML, Zikherman J, Tan AL, Lam VC, Cresalia NM, Oksenberg N, Goren N, Brassat D, Oksenberg JR, Weiss A.

Proc Natl Acad Sci U S A. 2009 Jan 13;106(2):546-51. doi: 10.1073/pnas.0811647106. Epub 2009 Jan 7.

16.

B cells drive lymphocyte activation and expansion in mice with the CD45 wedge mutation and Fas deficiency.

Gupta VA, Hermiston ML, Cassafer G, Daikh DI, Weiss A.

J Exp Med. 2008 Nov 24;205(12):2755-61. doi: 10.1084/jem.20081204. Epub 2008 Nov 10.

17.

Dysregulation of signaling pathways in CD45-deficient NK cells leads to differentially regulated cytotoxicity and cytokine production.

Hesslein DG, Takaki R, Hermiston ML, Weiss A, Lanier LL.

Proc Natl Acad Sci U S A. 2006 May 2;103(18):7012-7. Epub 2006 Apr 20.

18.

The juxtamembrane wedge negatively regulates CD45 function in B cells.

Hermiston ML, Tan AL, Gupta VA, Majeti R, Weiss A.

Immunity. 2005 Dec;23(6):635-47.

19.

A practical approach to the evaluation of the anemic child.

Hermiston ML, Mentzer WC.

Pediatr Clin North Am. 2002 Oct;49(5):877-91. Review.

PMID:
12430617
20.

CD45: a critical regulator of signaling thresholds in immune cells.

Hermiston ML, Xu Z, Weiss A.

Annu Rev Immunol. 2003;21:107-37. Epub 2001 Dec 19. Review.

PMID:
12414720
21.

Reciprocal regulation of lymphocyte activation by tyrosine kinases and phosphatases.

Hermiston ML, Xu Z, Majeti R, Weiss A.

J Clin Invest. 2002 Jan;109(1):9-14. Review. No abstract available.

22.

Phenotype of mice lacking functional Deleted in colorectal cancer (Dcc) gene.

Fazeli A, Dickinson SL, Hermiston ML, Tighe RV, Steen RG, Small CG, Stoeckli ET, Keino-Masu K, Masu M, Rayburn H, Simons J, Bronson RT, Gordon JI, Tessier-Lavigne M, Weinberg RA.

Nature. 1997 Apr 24;386(6627):796-804.

PMID:
9126737
23.
25.

Inflammatory bowel disease and adenomas in mice expressing a dominant negative N-cadherin.

Hermiston ML, Gordon JI.

Science. 1995 Nov 17;270(5239):1203-7.

PMID:
7502046
26.
28.

Differentiation and self-renewal in the mouse gastrointestinal epithelium.

Gordon JI, Hermiston ML.

Curr Opin Cell Biol. 1994 Dec;6(6):795-803. Review.

PMID:
7880525
30.
31.

Supplemental Content

Loading ...
Support Center